PURPOSE: Fractionated external beam radiotherapy (EBRT) +/- @entity3600 (BCNU) is the standard of care for @entity1 with @entity463 ( @entity463 ), but survival results remain poor. Preclinical studies indicate synergy between @entity138 and @entity1311 (TAX) in @entity816 cell lines. Phase I studies in @entity463 have demonstrated a maximum tolerated dose for TAX of 225 mg/m(2)/3 h/week x 6, during EBRT, with no exacerbation of typical @entity138 -induced @entity137 . The Radiation Therapy Oncology Group (RTOG) therefore mounted a Phase II study to determine the feasibility and efficacy of conventional EBRT and concurrent weekly TAX at its MTD. @entity1 AND METHODS: Sixty-two @entity1 with histologic diagnosis of @entity463 were enrolled from 8/16/96 through 3/21/97 in a multi-institutional Phase II trial of EBRT and TAX 225 mg/m(2)/3 h (1-3 h before EBRT), administered the first treatment day of each @entity138 week. Total EBRT dose was 60 Gy (200 cGy/fraction), 5 days per week. A smaller treatment field, to include gross disease plus a margin only, was used after 46 Gy. RESULTS: Sixty-one @entity1 (98%) were evaluable. Median age was 55 years (range, 28-78). Seventy-four percent were > or = 50 years. Recursive partitioning analysis (RPA) Classes III, IV, V, VI included 10 (17%), 21 (34%), 25 (41%), and 5 (8%) @entity1 , respectively. Gross total resection was performed in only 16%. There was no Grade 3 or 4 @entity1398 or @entity882 . @entity56 reactions precluding further use of TAX occurred in 4 @entity1 . There were 2 instances of late @entity2359 (4% Grade 3 or 4). Ninety-one percent of @entity1 received treatment per protocol. Seventy-seven percent completed prescribed treatment (6 weeks). Of 35 @entity1 with measurable disease, CR/PR was observed in 23%, MR in 17%, and @entity168 in 43%. Seventeen percent demonstrated progression at first follow-up. Median potential follow-up time is 20 months. Median survival is 9.7 months, with median survivals for RPA classes III, IV, V, and VI of 16.3, 10.2, 9.5, 2.5 months, respectively. Ten @entity1 remain alive. CONCLUSION: Concurrent full-dose EBRT and weekly high-dose TAX is feasible in the majority of @entity463 @entity1 . Acute @entity137 is acceptable; myelosuppression and @entity1897 are surprisingly modest, despite considerably higher overall dose intensity, compared to that achievable in other disease sites. Median survival by RPA class without prolonged adjuvant therapy is comparable to RTOG controls treated with standard EBRT and BCNU (1 year of BCNU).

Phase II radiation therapy oncology group trial of weekly @entity1311 and conventional external beam radiation therapy for XXXX multiforme.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity138 :: ('MESH:C563738', 'Disease') :: ['RT'] @entity168 :: ('MESH:D029461', 'Disease') :: ['SD'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity3600 :: ('MESH:D002330', 'Chemical') :: ['carmustine'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral sensory neuropathy'] @entity816 :: ('MESH:D001254', 'Disease') :: ['astrocytoma'] @entity56 :: ('MESH:D004342', 'Disease') :: ['Hypersensitivity'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma multiforme', 'GBM'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity']
@entity463 :: (MESH:D005909,Disease) :: ['supratentorial glioblastoma']
